Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Short

Showing results (101-110 of 346) with videos related to

Pageof 35
Sort By:
American Journal of Hematology|March 29, 2021
An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemiaNicholas J Short, Marina Konopleva, Tapan Kadia, et al.
Blood Advances|August 31, 2021
Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapseBachar Samra, Joseph D Khoury, Kiyomi Morita, et al.
British Journal of Haematology|May 9, 2024
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous diseaseWei-Ying Jen, Hagop Kantarjian, Tapan M Kadia, et al.
Blood Advances|September 30, 2021
Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemiaDavid McCall, Michael Roth, Kris M Mahadeo, et al.
Cancer|May 28, 2024
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phaseFadi G Haddad, Koji Sasaki, Lewis Nasr, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 13, 2025
Inferior Outcomes in Acute Lymphoblastic Leukemia With Translocation (14;18)Diane Habib, Elias Jabbour, Alex Bataller, et al.
Blood Advances|February 24, 2022
Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapySangeetha Venugopal, Gautam Borthakur, Naval Daver, et al.
Leukemia & Lymphoma|August 9, 2025
Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phaseOmer Karrar, Hagop Kantarjian, Fadi G Haddad, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2026
Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic LeukemiaWei-Ying Jen, Elias Jabbour, Eitan Kugler, et al.
American Journal of Hematology|November 6, 2018
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American expertsNicholas J Short, Elias Jabbour, Maher Albitar, et al.
Pageof 35

Showing results (101-110 of 346) with videos related to

Sort By:
Pageof 35
American Journal of Hematology|March 29, 2021
An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemiaNicholas J Short, Marina Konopleva, Tapan Kadia, et al.
Blood Advances|August 31, 2021
Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapseBachar Samra, Joseph D Khoury, Kiyomi Morita, et al.
British Journal of Haematology|May 9, 2024
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous diseaseWei-Ying Jen, Hagop Kantarjian, Tapan M Kadia, et al.
Blood Advances|September 30, 2021
Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemiaDavid McCall, Michael Roth, Kris M Mahadeo, et al.
Cancer|May 28, 2024
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phaseFadi G Haddad, Koji Sasaki, Lewis Nasr, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 13, 2025
Inferior Outcomes in Acute Lymphoblastic Leukemia With Translocation (14;18)Diane Habib, Elias Jabbour, Alex Bataller, et al.
Blood Advances|February 24, 2022
Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapySangeetha Venugopal, Gautam Borthakur, Naval Daver, et al.
Leukemia & Lymphoma|August 9, 2025
Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phaseOmer Karrar, Hagop Kantarjian, Fadi G Haddad, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2026
Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic LeukemiaWei-Ying Jen, Elias Jabbour, Eitan Kugler, et al.
American Journal of Hematology|November 6, 2018
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American expertsNicholas J Short, Elias Jabbour, Maher Albitar, et al.
Pageof 35